Medicenna is a clinical stage immunooncology company advancing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™. We are developing a unique set of tunable Superkines™ that can be fused with pro-apoptotic proteins to precisely deliver potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment and cancer stem cells without harming healthy cells.
Medicenna Announces Closing of Public Offering of $35 Million
Phase 2 Recurrent Glioblastoma Clinical Trial Open to Enrollment
Biotech Showcase Conference - January 13th to January 15th, 2019
IL-4 modulate the tumor microenviroment and response to cancer therapies